700
Participants
Start Date
May 24, 2019
Primary Completion Date
November 8, 2020
Study Completion Date
October 7, 2021
RGN-259
A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
Placebo
It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
Scott & Christie and Associates, PC, Cranberry Township
Piedmont Eye Center, Lynchburg
Oculus Research, Inc. at the Eye Care Center, Raleigh
Visual Eyes Optometric, Shelby
Total Eye Care, P.A., Memphis
The Eye Care Institute, Louisville
Whitson Vision, Indianapolis
Midwest Cornea Associates, LLC, Indianapolis
Bergstrom Eye Research, LLC, Fargo
Dovilan Wyatt MD, LLC, Chicago
Texan Eye/Keystone Research, Austin
Vision Institute, Colorado Springs
Mountain View Eye Center, Layton
Country Hills Eye Center, Ogden
Cornea and Cataract Consultants of Arizona, Phoenix
Center For Sight, Henderson
Eye Research Foundation, Newport Beach
Andover Eye Associates, Andover
Andover Eye Associates, Raynham
Andover Eye Associates, Warwick
ReGenTree, LLC
INDUSTRY